We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Kiniksa's Arcalyst continues strong revenue growth through rising physician adoption and patient awareness.
KNSA is advancing KPL-387, with phase II data expected in the second half of 2026.
Kiniksa is developing KPL-1161, with a first-in-human phase I study planned by the end of 2026.
Kiniksa Pharmaceuticals International (KNSA - Free Report) is making steady progress, with strong commercial performance of Arcalyst, the first FDA-approved therapy for patients aged 12 years and older with recurrent pericarditis, a severe, debilitating and chronic autoinflammatory cardiovascular disease. The product has consistently delivered robust revenue growth, supported by increasing physician adoption and expanding patient awareness.
Arcalyst: Key Growth Driver of Kiniksa
Arcalyst is a once-weekly subcutaneous inhibitor of IL-1α and IL-1β, originally discovered by Regeneron Pharmaceuticals (REGN - Free Report) . The therapy is FDA-approved for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome and muckle-wells syndrome and deficiency of IL-1 receptor antagonist (DIRA).
The product was licensed from REGN in 2017 under an exclusive worldwide agreement (excluding the Middle East and North Africa). Following FDA approval in March 2021 for recurrent pericarditis, Arcalyst has become Kiniksa's flagship commercial product, while also retaining approvals for CAPS and DIRA. The therapy is marketed across the United States through specialty pharmacies, with Kiniksa leading commercialization and sharing profits with Regeneron. The company is also expanding Arcalyst's global reach through its partnership with Huadong Pharmaceutical in China and continues to strengthen manufacturing capabilities while exploring additional indications, including cardiac sarcoidosis.
The FDA granted Breakthrough Therapy designation to the drug for recurrent pericarditis in 2019, followed by Orphan Drug exclusivity in the United States in 2021. In the same year, the European Commission granted Orphan Drug Designation for the treatment of idiopathic pericarditis, further validating its therapeutic potential.
Kiniksa benefits from meaningful product revenues generated by Arcalyst. The company expects 2026 Arcalyst net product revenues to be in the range of $930 million to $945 million, compared to prior guidance of $900 million to $920 million.
Over the past three months, KNSA shares have risen 24.4% compared with the industry’s 2.2% growth.
Image Source: Zacks Investment Research
Pipeline Progress Fuels KNSA’s Growth Outlook
To extend its leadership in IL-1-targeted therapies, Kiniksa is advancing its next-generation IL-1 pipeline with KPL-387, a monoclonal antibody IL-1 receptor antagonist currently in a phase II/III study for recurrent pericarditis. Phase II dose-finding data are expected in the second half of 2026, with the pivotal phase III study anticipated to begin by year-end. The company is conducting a supplemental phase II study to evaluate the transition of patients from standard therapies to KPL-387 monotherapy.
Another pipeline candidate, KPL-1161, an Fc-modified monoclonal antibody that acts as an IL-1 receptor antagonist and designed for quarterly subcutaneous dosing. The candidate is currently in preclinical development, with a phase I first-in-human study expected to commence by the end of 2026.
Kiniksa Pharmaceuticals International, plc Price and Consensus
Kiniksa currently sports a Zacks Rank #1 (Strong Buy). Over the past 60 days, earnings per share estimates for Kiniksa have risen from $1.09 to $1.24 and the same for 2027 have also increased from $1.54 to $1.70.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have improved from 88 cents to earnings per share of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have gained 123% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
Key Takeaways
Kiniksa Pharmaceuticals International (KNSA - Free Report) is making steady progress, with strong commercial performance of Arcalyst, the first FDA-approved therapy for patients aged 12 years and older with recurrent pericarditis, a severe, debilitating and chronic autoinflammatory cardiovascular disease. The product has consistently delivered robust revenue growth, supported by increasing physician adoption and expanding patient awareness.
Arcalyst: Key Growth Driver of Kiniksa
Arcalyst is a once-weekly subcutaneous inhibitor of IL-1α and IL-1β, originally discovered by Regeneron Pharmaceuticals (REGN - Free Report) . The therapy is FDA-approved for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome and muckle-wells syndrome and deficiency of IL-1 receptor antagonist (DIRA).
The product was licensed from REGN in 2017 under an exclusive worldwide agreement (excluding the Middle East and North Africa). Following FDA approval in March 2021 for recurrent pericarditis, Arcalyst has become Kiniksa's flagship commercial product, while also retaining approvals for CAPS and DIRA. The therapy is marketed across the United States through specialty pharmacies, with Kiniksa leading commercialization and sharing profits with Regeneron. The company is also expanding Arcalyst's global reach through its partnership with Huadong Pharmaceutical in China and continues to strengthen manufacturing capabilities while exploring additional indications, including cardiac sarcoidosis.
The FDA granted Breakthrough Therapy designation to the drug for recurrent pericarditis in 2019, followed by Orphan Drug exclusivity in the United States in 2021. In the same year, the European Commission granted Orphan Drug Designation for the treatment of idiopathic pericarditis, further validating its therapeutic potential.
Kiniksa benefits from meaningful product revenues generated by Arcalyst. The company expects 2026 Arcalyst net product revenues to be in the range of $930 million to $945 million, compared to prior guidance of $900 million to $920 million.
Over the past three months, KNSA shares have risen 24.4% compared with the industry’s 2.2% growth.
Image Source: Zacks Investment Research
Pipeline Progress Fuels KNSA’s Growth Outlook
To extend its leadership in IL-1-targeted therapies, Kiniksa is advancing its next-generation IL-1 pipeline with KPL-387, a monoclonal antibody IL-1 receptor antagonist currently in a phase II/III study for recurrent pericarditis. Phase II dose-finding data are expected in the second half of 2026, with the pivotal phase III study anticipated to begin by year-end. The company is conducting a supplemental phase II study to evaluate the transition of patients from standard therapies to KPL-387 monotherapy.
Another pipeline candidate, KPL-1161, an Fc-modified monoclonal antibody that acts as an IL-1 receptor antagonist and designed for quarterly subcutaneous dosing. The candidate is currently in preclinical development, with a phase I first-in-human study expected to commence by the end of 2026.
Kiniksa Pharmaceuticals International, plc Price and Consensus
Kiniksa Pharmaceuticals International, plc price-consensus-chart | Kiniksa Pharmaceuticals International, plc Quote
KNSA's Zacks Rank & Estimates
Kiniksa currently sports a Zacks Rank #1 (Strong Buy). Over the past 60 days, earnings per share estimates for Kiniksa have risen from $1.09 to $1.24 and the same for 2027 have also increased from $1.54 to $1.70.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have improved from 88 cents to earnings per share of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 12% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have gained 123% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.